# US 2025/0059276 A1 · Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059276 A1
- Document ID: US20250059276A1
- Status: Published application
- Kind: A1
- Application number: 18/763,821
- Filed: 2024-07-03
- Published: 2025-02-20
- Earliest claimed: 2017-05-31
- Assignees: Stcube, Inc.
- Applicants: Stcube & Co., Inc.
- Inventors: Stephen Sunghan Yoo; Ezra Myung Chul Chung; Yong-Sik Bong; Yong-Soo Kim; Andrew H. Park
- Web page: https://patentgrep.com/patent/US20250059276A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 9/0029: {Parenteral nutrition; Parenteral nutrition compositions as drug carriers}
- A61P 35/00: Antineoplastic agents
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.

## Claims

### Claim at position 1

1-111. (canceled)

### Claim 112

A method of detecting an expression level of BTN1A1 comprising contacting a sample from a subject with an anti-BTN1A1 antibody or antigen-binding fragment thereof, and detecting the presence of the anti-BTN1A1 antibody or antigen-binding fragment thereof bound to the sample, wherein the antibody or antigen-binding fragment thereof immunospecifically binds to BTN1A1, wherein the expression level of BTN1A1 in the sample is compared to a reference level.

### Claim 113 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof, binds to glycosylated BTN1A1 in the sample.

### Claim 114 (depends on 113)

The method of claim 113, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof binds to glycosylated BTN1A1 at positions N55, N215, and/or N449.

### Claim 115 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof binds to dimeric BTN1A1.

### Claim 116 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises:
(i) (a) a heaving chain variable region (VH) comprising a VH complementarity-determining region (CDR) 1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:3; and
(b) a light chain variable domain (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:5;
or
(ii) (a) a heavy chain variable region (VH) comprising:
(1) a VH complementarity-determining region (CDR) 1 having an amino acid sequence of SEQ ID NO:7;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO:8; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:9;
and
(b) a light chain variable region (VL) comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:19;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:20; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:21;
or
(iii) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 10;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 11; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 12;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:22;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:23; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:24; or
or
(iv) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 13;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 14; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 15;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:25;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:26; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:27;
or
(v) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 16;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 17; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 18;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:28;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:29; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:30.

### Claim 117

The method of 116, wherein the anti-BTN1A1 antibody or the antigen-binding fragment thereof comprises
(a) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:3;
(b) a VH comprising an amino acid sequence of SEQ ID NO:3;
(c) a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:5;
(d) a VL comprising an amino acid sequence of SEQ ID NO:5; or
(e) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:3; and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:5.

### Claim 118 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or the antigen-binding fragment thereof comprises a VH comprising an amino acid sequence of SEQ ID NO:3 and a VL comprising an amino acid sequence of SEQ ID NO:5.

### Claim 119 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises:
(i) (a) VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:115; and
(b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:117;
or
(ii) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:119;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 120; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:121;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:131;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO: 132; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO: 133;
or
(iii) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:122;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 123; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:124;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO: 134;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:135; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO: 136;
or
(iv) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:125;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 126; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:127;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:137;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:138; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO: 139;
or
(v) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 128;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 129; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:130;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:140;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:141; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO: 142.

### Claim 120 (depends on 119)

The method of claim 119, wherein the anti-BTN1A1 antibody or the antigen-binding fragment thereof comprises:
(a) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:115;
(b) a VH comprising an amino acid sequence of SEQ ID NO:115;
(c) a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:117;
(d) a VL comprising an amino acid sequence of SEQ ID NO:117; or
(e) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:115; and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:117.

### Claim 121 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or the antigen-binding fragment thereof comprises a VH comprising an amino acid sequence of SEQ ID NO:115 and a VL comprising an amino acid sequence of SEQ ID NO:117.

### Claim 122 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises:
(i) (a) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:143; and
(b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:145;
or
(ii) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 147;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 148; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 149;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:159;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO: 160; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:161;
or
(iii) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 150;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO:151; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 152;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:162;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:163; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:164;
or
(iv) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 153;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 154; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 155;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:165;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO: 166; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:167;
or
(v) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:156;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 157; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 158;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO: 168;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO: 169; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:170.

### Claim 123 (depends on 122)

The method of claim 122, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises:
(a) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:143;
(b) a VH comprising an amino acid sequence of SEQ ID NO:143;
(c) a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:145;
(d) a VL comprising an amino acid sequence of SEQ ID NO:145; or
(e) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:143; and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:145.

### Claim 124 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises a VH comprising an amino acid sequence of SEQ ID NO:143 and a VL comprising an amino acid sequence of SEQ ID NO:145.

### Claim 125 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises:
(i) (a) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having an amino acid sequence of SEQ ID NO:227; and
(b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having an amino acid sequence of SEQ ID NO:229;
or
(ii) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:231;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO:232; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:233;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:243;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:244; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:245;
or
(iii) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:234;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO:235; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:236;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:246;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:247; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:248;
or
(iv) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:237;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO:238; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:239;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:249;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:250; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:251;
or
(v) (a) a VH comprising:
(1) a VH CDR1 having an amino acid sequence of SEQ ID NO:240;
(2) a VH CDR2 having an amino acid sequence of SEQ ID NO:241; and
(3) a VH CDR3 having an amino acid sequence of SEQ ID NO:242;
and
(b) a VL comprising:
(1) a VL CDR1 having an amino acid sequence of SEQ ID NO:252;
(2) a VL CDR2 having an amino acid sequence of SEQ ID NO:253; and
(3) a VL CDR3 having an amino acid sequence of SEQ ID NO:254.

### Claim 126 (depends on 125)

The method of claim 125, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises:
(a) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:227;
(b) a VH comprising an amino acid sequence of SEQ ID NO:227;
(c) a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:229;
(d) a VL comprising an amino acid sequence of SEQ ID NO:229; or
(e) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:227; and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:229.

### Claim 127 (depends on 112)

The method of claim 112, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises a VH comprising an amino acid sequence of SEQ ID NO:227 and a VL comprising an amino acid sequence of SEQ ID NO:229.

### Claim 128 (depends on 112)

The method of claim 112, wherein the method further comprises providing cancer diagnosis in the subject by:
i) contacting the sample from the subject with the anti-BTN1A1 antibody or antigen-binding fragment thereof to form a complex between the antibody or antigen-binding fragment thereof and BTN1A1;
ii) detecting the complex; and
iii) diagnosing the subject as likely having cancer if the complex is detected in the sample.

### Claim 129 (depends on 128)

The method of claim 128, wherein the cancer can be a hematological cancer or a solid tumor.

### Claim 130 (depends on 129)

The method of claim 129, wherein the hematological cancer is selected from the group consisting of leukemia, lymphoma, and myeloma.

### Claim 131 (depends on 129)

The method of claim 129, wherein the solid tumor is selected from the group consisting of breast cancer, lung cancer, thymic cancer, thyroid cancer, head & neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, kidney cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer or skin cancer.

### Claim 132 (depends on 128)

The method of claim 128, wherein the sample is selected from the group consisting of a blood, whole blood, bone marrow, partially purified blood, PBMCs, a tissue biopsy, or circulating tumor cells.

### Claim 133 (depends on 128)

The method of claim 128, wherein the anti-BTN1A1 antibody or antigen-binding fragment thereof comprises a label for detecting the complex.

### Claim 134 (depends on 133)

The method of claim 133, wherein the label is selected from the group consisting of a radioactive label, a fluorescent label, a hapten, an enzyme, or a secondary antibody.

### Claim 135 (depends on 128)

The method of claim 128, wherein the complex is detected by an assay.

### Claim 136 (depends on 135)

The method of claim 135, wherein the assay is selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA), a fluorescent immunosorbent assay (FIA), a chemiluminescent immunosorbent assay (CLIA), a radioimmunoassay (RIA), an enzyme multiplied immunoassay (EMI), a solid phase radioimmunoassay (SPROA), a fluorescence polarization (FP) assay, a fluorescence resonance energy transfer (FRET) assay, a time-resolved fluorescence resonance energy transfer (TR-FRET) assay, and a surface plasmon resonance (SPR) assay.
